Nicotine and sympathetic neurotransmission Markus HaassWolfgang Kübler Applied Pharmacology Pages: 657 - 665
Effects of KT-362, a sarcolemmal and intracellular calcium antagonist, on calcium transients of cultured neonatal rat ventricular cells: A comparison with gallopamil and ryanodine Youichi TatsukawaMakoto Arita Applied Pharmacology Pages: 667 - 675
Heart rate and heart rate variability, a pharmacological target Bernard SwynghedauwSylvain JassonFrançois Carré Applied Pharmacology Pages: 677 - 685
Clinical efficacy of propantheline bromide in neurocardiogenic syncope: Pharmacodynamic implications John C. L. YuRuey J. Sung Applied Pharmacology Pages: 687 - 692
Current and newer approaches in the drug treatment of congestive heart failure P. A. van Zwieten Congestive Heart Failure Pages: 693 - 702
Intropic agents in the treatment of heart failure: Despair or hope? Shigetake Sasayama Congestive Heart Failure Pages: 703 - 709
Medical treatment of heart failure: The Canadian Cardiovascular Society's Consensus Conference revisited Pascal VantrimpontJean L. Rouleau Congestive Heart Failure Pages: 711 - 716
Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans Gabor SütschOsmund BertelWolfgang Kiowski Congestive Heart Failure Pages: 717 - 725
The case for low-dose aspirin for the prevention of myocardial infarction: But how low is low? Werner FörsterJames Roy Parratt Coronary Artery Disease Pages: 727 - 734
Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure Udho Thadani Coronary Artery Disease Pages: 735 - 742
Hemostatic variables and ischemic cardiovascular disease: Do we need a concerted effort for more profitable future clinical investigations? Giovanni Di MinnoFrancesco Paolo ManciniMaurizio Margaglione Coronary Artery Disease Pages: 743 - 749
The risk and cost-effective individual patient management: The challenge of a new generation of clinical trials Attilio MaseriDomenico CianfloneFilippo Crea Trial Design Pages: 751 - 758
Controversies in preconditioning Jan Willem de JongRobert de JongeSilvia Bradamante Preconditioning Pages: 767 - 773
Does protein kinase C play a pivotal role in the mechanisms of ischemic preconditioning? Ben C. G. GhoYvonne E. G.Pieter D. Verdouw Preconditioning Pages: 775 - 786
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia Sylvie PerreaultVivian H. HamiltonSteven Grover Lipids Pages: 787 - 794
Effects of antihypertensive drugs on various aspects of renal function Peter W. de LeeuwWillem H. Birkenhäger Hypertension Pages: 803 - 808
